Pyxis Oncology (PYXS) Competitors

Kamada (NASDAQ:KMDA) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.

Does the media prefer KMDA or PYXS?

In the previous week, Kamada had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 2 mentions for Kamada and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.73 beat Kamada's score of 0.33 indicating that Kamada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is KMDA or PYXS more profitable?

Kamada has a net margin of 5.81% compared to Kamada's net margin of 0.00%. Pyxis Oncology's return on equity of 5.66% beat Kamada's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	5.81%	5.66%	3.57%
Pyxis Oncology	N/A	-52.60%	-41.08%

Do analysts prefer KMDA or PYXS?

Kamada presently has a consensus target price of $11.00, suggesting a potential upside of 115.69%. Pyxis Oncology has a consensus target price of $8.50, suggesting a potential upside of 87.64%. Given Pyxis Oncology's higher probable upside, research analysts clearly believe Kamada is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pyxis Oncology	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, KMDA or PYXS?

Kamada has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Do insiders & institutionals believe in KMDA or PYXS?

20.4% of Kamada shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 8.4% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer KMDA or PYXS?

Kamada received 290 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 78.26% of users gave Pyxis Oncology an outperform vote while only 64.98% of users gave Kamada an outperform vote.

Company	Underperform	Outperform
Kamada	Outperform Votes 308 64.98%	Underperform Votes 166 35.02%
Pyxis Oncology	Outperform Votes 18 78.26%	Underperform Votes 5 21.74%

Which has higher earnings & valuation, KMDA or PYXS?

Kamada has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$142.52M	2.06	$8.28M	$0.15	34.00
Pyxis Oncology	N/A	N/A	-$73.79M	-$1.84	-2.46

Summary

Kamada beats Pyxis Oncology on 12 of the 16 factors compared between the two stocks.